{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myxoid+Round+Cell+Liposarcoma", "query": { "condition": "Myxoid Round Cell Liposarcoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myxoid+Round+Cell+Liposarcoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T17:58:07.021Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06414434", "title": "BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liposarcoma", "Recurrent Liposarcoma", "Metastatic Liposarcoma", "Unresectable Liposarcoma", "MDM2 Gene Amplification", "Myxoid Liposarcoma", "CIC-Rearranged Sarcoma" ], "interventions": [ { "name": "BTX-A51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Wagner, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-09-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06414434" }, { "nct_id": "NCT06239272", "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adipocytic Neoplasm", "Liposarcoma", "Atypical Fibroxanthoma", "Angiomatoid Fibrous Histiocytoma", "Myoepithelioma", "Fibrosarcoma NOS", "Myxofibrosarcoma", "Angiosarcoma", "Osteosarcoma, Extraskeletal" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "Proton beam radiation therapy", "type": "RADIATION" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 139, "start_date": "2024-03-27", "completion_date": "2037-06", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239272" }, { "nct_id": "NCT03967223", "title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Letetresgene autoleucel (lete-cel, GSK3377794)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "USWM CT, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 103, "start_date": "2019-12-31", "completion_date": "2026-07-31", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 24, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03967223" }, { "nct_id": "NCT02059850", "title": "NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Synovial Sarcoma", "Myxoid/Round Cell Liposarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage IV Adult Soft Tissue Sarcoma" ], "interventions": [ { "name": "Autologous NY-ESO-1-specific CD8-positive T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-02-03", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059850" }, { "nct_id": "NCT01477021", "title": "Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Liposarcoma", "Adult Synovial Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage IV Adult Soft Tissue Sarcoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "NY-ESO-1-specific T cells", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-11", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01477021" }, { "nct_id": "NCT06083883", "title": "Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Synovial Sarcoma", "Myxoid/Round Cell Liposarcoma" ], "interventions": [ { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "NY-ESO-1 TCR/IL-15 NK", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 44, "start_date": "2024-03-27", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06083883" }, { "nct_id": "NCT03132922", "title": "MAGE-A4ᶜ¹º³²T for Multi-Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Cancer", "Melanoma", "Head and Neck Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Synovial Sarcoma", "Myxoid Round Cell Liposarcoma", "Gastroesophageal Junction" ], "interventions": [ { "name": "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells", "type": "GENETIC" }, { "name": "Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation", "type": "RADIATION" } ], "intervention_types": [ "GENETIC", "RADIATION" ], "sponsor": "USWM CT, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 71, "start_date": "2017-05-15", "completion_date": "2032-09", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 10, "location_summary": "Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132922" }, { "nct_id": "NCT04526509", "title": "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3901961", "type": "DRUG" }, { "name": "GSK3845097", "type": "DRUG" }, { "name": "GSK4427296", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adaptimmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-12-21", "completion_date": "2023-06-08", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 9, "location_summary": "Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04526509" }, { "nct_id": "NCT03600649", "title": "Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Myxoid Liposarcoma", "Sarcoma,Soft Tissue", "Desmoplastic Small Round Cell Tumor", "Extraskeletal Myxoid Chondrosarcoma", "Angiomatoid Fibrous Histiocytoma", "Clear Cell Sarcoma", "Primary Pulmonary Myxoid Sarcoma", "Myoepithelial Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Fibromyxoid Tumor" ], "interventions": [ { "name": "Seclidemstat", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Salarius Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 50, "start_date": "2018-06-04", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Monica, California • Jacksonville, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600649" }, { "nct_id": "NCT05266196", "title": "A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "Myxoid Liposarcoma", "Desmoplastic Small Round Cell Tumor", "Extraskeletal Myxoid Chondrosarcoma", "Angiomatoid Fibrous Histiocytoma", "Clear Cell Sarcoma", "Myoepithelial Tumor", "Low Grade Fibromyxoid Sarcoma", "Sclerosing Epithelioid Fibrosarcoma" ], "interventions": [ { "name": "Seclidemstat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Salarius Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 10, "start_date": "2022-01-15", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-06-25T17:58:07.021Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05266196" } ] }